<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01416402</url>
  </required_header>
  <id_info>
    <org_study_id>M102-21124</org_study_id>
    <nct_id>NCT01416402</nct_id>
  </id_info>
  <brief_title>Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients</brief_title>
  <official_title>A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Arhalofenate (MBX-102) in Combination With Febuxostat for the Treatment of Hyperuricemia in Patients With Gout</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CymaBay Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CymaBay Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether arhalofenate is safe and effective when&#xD;
      dosed in combination with febuxostat in lowering serum uric acid in patients with gout.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients achieving sUA &lt;6.0 mg/dL, &lt;5.0 mg/dL, &lt;4.0 mg/dL and &lt;3.0 mg/dL at the end of combination treatment period with each of the doses of arhalofenate</measure>
    <time_frame>36 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Hyperuricemia</condition>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>Arhalofenate with febuxostat and colchicine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arhalofenate</intervention_name>
    <description>400 mg once daily orally for two weeks then up-titrated to 600 mg once daily orally for an additional two weeks</description>
    <arm_group_label>Arhalofenate with febuxostat and colchicine</arm_group_label>
    <other_name>MBX-102</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat</intervention_name>
    <description>80 mg once daily orally for 5 weeks</description>
    <arm_group_label>Arhalofenate with febuxostat and colchicine</arm_group_label>
    <other_name>Uloric</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>Colchicine 0.6 mg daily as prophylaxis to prevent gout flares</description>
    <arm_group_label>Arhalofenate with febuxostat and colchicine</arm_group_label>
    <other_name>Colcrys</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Known gout patient (per criteria of the American Rheumatism Association for the&#xD;
             classification of the acute arthritis of primary gout in Appendix 3) with a serum uric&#xD;
             acid value of at least 8.0 mg/dL at Screening Visit. Patients on allopurinol must&#xD;
             agree to discontinue their existing therapy at Visit 1 through the entire duration of&#xD;
             the study and must have a sUA value of at least 8.0 mg/dL after a minimum 2 week&#xD;
             wash-out at Visit 2.&#xD;
&#xD;
          2. Male or female, 18-75 years of age at Screening Visit&#xD;
&#xD;
          3. All female patients must be surgically sterile or post-menopausal (at least 45 years&#xD;
             of age with no history of menses for at least 2 years; or any age with no history of&#xD;
             menses for at least 6 months and serum FSH ≥ 40 mIU/mL) or must agree to use two&#xD;
             medically accepted methods of contraception including a barrier method (see the list&#xD;
             in Appendix 4) for the entire duration of the study unless report of complete sexual&#xD;
             abstinence.&#xD;
&#xD;
          4. Female patients must not be pregnant or lactating&#xD;
&#xD;
          5. Male patients with a female partner of child-bearing potential must agree to use&#xD;
             condom or the partner must use a medically acceptable method of contraception for the&#xD;
             entire duration of the study.&#xD;
&#xD;
          6. Estimated CrCl ≥ 50 mL/min as calculated by the by Cockcroft-Gault method&#xD;
&#xD;
          7. Serum creatinine value must be ≤ 1.3 mg/dL in females and ≤ 1.4 mg/dL in males&#xD;
&#xD;
          8. Patients must have liver function tests (LFTs) ≤ 1.5X ULN for AST, ALT and&#xD;
             T-bilirubin, ≤ 2X ULN for ALP, ≤ 3X ULN for GGT; CK ≤ 3X ULN&#xD;
&#xD;
          9. All other clinical laboratory parameters must be within normal limits or considered&#xD;
             not clinically significant&#xD;
&#xD;
         10. Electrocardiogram (ECG) must be normal, or if abnormal, considered not clinically&#xD;
             significant&#xD;
&#xD;
         11. Patients must have a systolic blood pressure ≤ 160 mm Hg and a diastolic blood&#xD;
             pressure ≤ 95 mm Hg; known hypertensive patients controlled with medication other than&#xD;
             diuretics (BP reading as above) may be included&#xD;
&#xD;
         12. Patients must agree to remain in-clinic for 37 days consecutively and agree to follow&#xD;
             the study procedures as described in the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Treatment with any ULT other than allopurinol (e.g., probenecid, benzbromarone,&#xD;
             febuxostat, or pegloticase) within two weeks of the Screening Visit&#xD;
&#xD;
          2. Known or suspected secondary hyperuricemia (e.g. due to myeloproliferative disorder,&#xD;
             or organ transplant).&#xD;
&#xD;
          3. Diagnosis of xanthinuria&#xD;
&#xD;
          4. History of documented or suspected kidney stones&#xD;
&#xD;
          5. Known infection with the human immunodeficiency virus (HIV) or history of viral&#xD;
             hepatitis type B or C&#xD;
&#xD;
          6. History of illicit drug or alcohol abuse within one year of Screening Visit&#xD;
&#xD;
          7. History of significant pulmonary disease, upper gastrointestinal (GI) bleeding,&#xD;
             documented peptic ulcer disease (unless known H. pylori infection treated successfully&#xD;
             without recurrence), or nephrotic syndrome within three years of Screening Visit&#xD;
&#xD;
          8. History of stroke, TIA, acute myocardial infarction (MI), congestive heart failure&#xD;
             (CHF) (NYHA Class II-IV), angina pectoris, coronary intervention procedure (including&#xD;
             but not limited to angioplasty, stent placement, coronary revascularization), lower&#xD;
             extremity bypass procedure, systemic or intracoronary fibrinolytic therapy within 5&#xD;
             years of screening&#xD;
&#xD;
          9. Malignancy within five years of Screening Visit (except successfully treated basal&#xD;
             cell carcinoma)&#xD;
&#xD;
         10. Body mass index (BMI) &gt; 42 kg/m2&#xD;
&#xD;
         11. Current or expected requirement for anticoagulant therapy [except for low-dose (≤ 325&#xD;
             mg/day) aspirin and/or Plavix® 75 mg/day]&#xD;
&#xD;
         12. Rheumatoid arthritis or other autoimmune disease requiring ongoing treatment&#xD;
&#xD;
         13. Current or expected treatment with potent CYP3A4 inhibitors (See Appendix 6),&#xD;
             cytotoxic agents (azathioprine, mercaptopurine, cyclosporine, cyclophosphamide, etc.),&#xD;
             ranolazine, digoxin, theophyline, desipramine, sulphonylurea, thiazolidinedione,&#xD;
             diuretics, atypical antipsychotic agents, or phenytoin&#xD;
&#xD;
         14. Chronic treatment with non-steroidal anti-inflammatory drugs (NSAIDs use to treat&#xD;
             acute gout flares is permitted)&#xD;
&#xD;
         15. Current or expected treatment with systemic corticosteroids (except topical,&#xD;
             ophthalmic, intra-articular, or inhaled at a dose &lt; 1600 μg/day) other than to treat&#xD;
             acute gout flares&#xD;
&#xD;
         16. Known hypersensitivity to colchicine or febuxostat&#xD;
&#xD;
         17. Treatment with any other investigational therapy within the 30 days prior to the&#xD;
             Screening Visit, or patients who received at least one dose of blinded study&#xD;
             medication while enrolled in any previous arhalofenate trial&#xD;
&#xD;
         18. Any other condition that compromises the ability of the patient to provide informed&#xD;
             consent or to comply with the objectives and procedures of this protocol, as judged by&#xD;
             the investigator and/or medical monitor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>August 11, 2011</study_first_submitted>
  <study_first_submitted_qc>August 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2011</study_first_posted>
  <disposition_first_submitted>February 19, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>March 9, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 3, 2015</disposition_first_posted>
  <last_update_submitted>March 9, 2015</last_update_submitted>
  <last_update_submitted_qc>March 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperuricemia</keyword>
  <keyword>gout</keyword>
  <keyword>serum uric acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
    <mesh_term>Febuxostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

